Key highlights
- Ryan Koors is appointed VP, Investor Relations effective May 7, 2026.
- He will report to CFO Joseph J. Wolk and succeeds Darren Snellgrove, who is leaving to become CFO of Halozyme.
- Koors has 20+ years at the company in finance leadership across Innovative Medicine R&D, MedTech surgery and supply chain, most recently serving as CFO/VP Finance for Innovative Medicine Global R&D.
Appointment
Ryan Koors will become Vice President, Investor Relations at Johnson & Johnson, effective May 7, 2026; he will report to Executive Vice President and Chief Financial Officer Joseph J. Wolk.
Succession
Koors succeeds Darren Snellgrove, who is leaving to become chief financial officer of Halozyme.
Background
Koors has more than 20 years at Johnson & Johnson in senior finance roles across Innovative Medicine, Global Research & Development, MedTech surgery and supply chain; he most recently served as Chief Financial Officer and Vice President of Finance for Innovative Medicine Global R&D. He joined the company in 2002 and holds a bachelor’s degree in finance from Wright State University and an MBA from Xavier University.
